Epigenetic regulation of chromosomal instability by EZH2 methyltransferase.

IF 33.3 1区 医学 Q1 ONCOLOGY
Yang Bai,Albert S Agustinus,Shira Yomtoubian,Cem Meydan,Dylan R McNally,Liron Yoffe,Melissa J Hubisz,Marvel Tranquille,Sneha Pramod,Christy Hong,Magdalena L Plasilova,Aakanksha R Kapoor,Arshdeep Singh,Henry Withers,Lukas E Dow,Ashley M Laughney,Bhavneet Bhinder,Olivier Elemento,Ari M Melnick,Samuel F Bakhoum,Vivek Mittal
{"title":"Epigenetic regulation of chromosomal instability by EZH2 methyltransferase.","authors":"Yang Bai,Albert S Agustinus,Shira Yomtoubian,Cem Meydan,Dylan R McNally,Liron Yoffe,Melissa J Hubisz,Marvel Tranquille,Sneha Pramod,Christy Hong,Magdalena L Plasilova,Aakanksha R Kapoor,Arshdeep Singh,Henry Withers,Lukas E Dow,Ashley M Laughney,Bhavneet Bhinder,Olivier Elemento,Ari M Melnick,Samuel F Bakhoum,Vivek Mittal","doi":"10.1158/2159-8290.cd-25-0947","DOIUrl":null,"url":null,"abstract":"Chromosomal instability (CIN) and epigenetic reprogramming are central drivers of breast cancer progression, yet the mechanisms connecting them remain elusive. We uncover a direct role of EZH2 histone methyltransferase in promoting CIN in triple-negative breast cancer (TNBC). Across breast cancers, EZH2 expression correlates with copy number alterations, and its catalytic activity is associated with increased CIN in metastasis-initiating cells. Pharmacological EZH2 inhibition suppressed CIN, revealing an unexpected vulnerability. Integrated chromatin and transcriptome profiling identified Tankyrase (TNKS), a poly(ADP-ribose) polymerase, as a direct transcriptional target of EZH2. Mechanistically, EZH2-mediated TNKS suppression disrupts CPAP (centrosomal P4.1-associated protein), driving centrosome overduplication, multipolar mitosis and exacerbated CIN. In vivo, CIN suppression is a critical mechanism underlying the anti-metastatic effects of EZH2 inhibition. These findings delineate a previously unrecognized epigenetic mechanism governing CIN and establish EZH2 inhibitors as the first therapeutic agents capable of directly suppressing CIN, underscoring the need for trials with metastasis-focused endpoints.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"22 1","pages":""},"PeriodicalIF":33.3000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2159-8290.cd-25-0947","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Chromosomal instability (CIN) and epigenetic reprogramming are central drivers of breast cancer progression, yet the mechanisms connecting them remain elusive. We uncover a direct role of EZH2 histone methyltransferase in promoting CIN in triple-negative breast cancer (TNBC). Across breast cancers, EZH2 expression correlates with copy number alterations, and its catalytic activity is associated with increased CIN in metastasis-initiating cells. Pharmacological EZH2 inhibition suppressed CIN, revealing an unexpected vulnerability. Integrated chromatin and transcriptome profiling identified Tankyrase (TNKS), a poly(ADP-ribose) polymerase, as a direct transcriptional target of EZH2. Mechanistically, EZH2-mediated TNKS suppression disrupts CPAP (centrosomal P4.1-associated protein), driving centrosome overduplication, multipolar mitosis and exacerbated CIN. In vivo, CIN suppression is a critical mechanism underlying the anti-metastatic effects of EZH2 inhibition. These findings delineate a previously unrecognized epigenetic mechanism governing CIN and establish EZH2 inhibitors as the first therapeutic agents capable of directly suppressing CIN, underscoring the need for trials with metastasis-focused endpoints.
EZH2甲基转移酶对染色体不稳定性的表观遗传调控。
染色体不稳定性(CIN)和表观遗传重编程是乳腺癌进展的核心驱动因素,但它们之间的联系机制仍然难以捉摸。我们发现EZH2组蛋白甲基转移酶在三阴性乳腺癌(TNBC)中促进CIN的直接作用。在乳腺癌中,EZH2的表达与拷贝数的改变有关,其催化活性与转移起始细胞中CIN的增加有关。药理EZH2抑制抑制CIN,揭示出意想不到的脆弱性。综合染色质和转录组分析鉴定了Tankyrase (TNKS),一种聚(adp -核糖)聚合酶,作为EZH2的直接转录靶点。在机制上,ezh2介导的TNKS抑制破坏CPAP(中心体p4.1相关蛋白),驱动中心体过度复制,多极有丝分裂和加剧CIN。在体内,抑制CIN是抑制EZH2抗转移作用的关键机制。这些发现描述了一种以前未被认识到的控制CIN的表观遗传机制,并确立了EZH2抑制剂作为第一种能够直接抑制CIN的治疗药物,强调了以转移为中心的终点进行试验的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer discovery
Cancer discovery ONCOLOGY-
CiteScore
22.90
自引率
1.40%
发文量
838
审稿时长
6-12 weeks
期刊介绍: Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信